PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

BACKGROUND: Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need to identify patients more likely to benefit from AA. Parameters link...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Manag Res
Asıl Yazarlar: España, Sofia, Ochoa de Olza, Maria, Sala, Nuria, Piulats, Josep Maria, Ferrandiz, Ulises, Etxaniz, Olatz, Heras, Lucia, Buisan, Oscar, Pardo, Juan Carlos, Suarez, Jose F, Barretina, Pilar, Comet, Josep, Garcia del Muro, Xavier, Sumoy, Lauro, Font, Albert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7584507/
https://ncbi.nlm.nih.gov/pubmed/33116879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S270392
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller